Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD of AZD4144 and DDI with Rosuvastatin/Furosemide
NCT06491550Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD4144 in chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Area under plasma concentration-time curve from time 0 to infinity and 2 more. Started Jul 2024; status: completed.
02
Drugs
AZD4144
03
Conditions
chronic kidney disease (CKD)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06491550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06491550.